Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur
2012 (English)In: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 158, no 3, 355-362 p.Article in journal (Refereed) Published
Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early based on the median observation time of 4 years results of the Nordic Lymphoma Group MCL2 study of frontline intensive induction immunochemotherapy and autologous stem cell transplantation (ASCT), with more than 60% event-free survival at 5 years, and no subsequent relapses reported. Here we present an update after a median observation time of 6.5 years. The overall results are still excellent, with median overall survival and response duration longer than 10 years, and a median event-free survival of 7.4 years. However, six patients have now progressed later than 5 years after end of treatment. The international MCL Prognostic Index (MIPI) and Ki-67-expression were the only independent prognostic factors. Subdivided by the MIPI-Biological Index (MIPI + Ki-67, MIPI-B), more than 70% of patients with low-intermediate MIPI-B were alive at 10 years, but only 23% of the patients with high MIPI-B. These results, although highly encouraging regarding the majority of the patients, underline the need of a risk-adapted treatment strategy for MCL.
Place, publisher, year, edition, pages
2012. Vol. 158, no 3, 355-362 p.
mantle cell lymphoma, autologous stem cell transplant, high-dose AraC, rituximab, pre-emptive therapy
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-179002DOI: 10.1111/j.1365-2141.2012.09174.xISI: 000306307500008OAI: oai:DiVA.org:uu-179002DiVA: diva2:543261
Correction in British Journal of Haematology, vol 158, issue 6, 2012, pages 815-816.
DOI: 10.1111/bjh.120062012-08-072012-08-062012-10-01Bibliographically approved